AOBiome Therapeutics Appoints Todd Krueger as Chief Executive Officer

Latest News

AOBiome Therapeutics Appoints Todd Krueger as Chief Executive Officer

Cambridge, MA, January 4, 2018
AOBiome Therapeutics (“AOBiome”) today announced that Todd Krueger has been named Chief Executive Officer, effective immediately. Mr. Krueger retains his current role as President, a position he has held since March 2016. AOBiome is a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions.

“We are very pleased to have Todd take on the role of CEO at this pivotal time for AOBiome,” said AOBiome’s Chairman and Co-Founder Jamie Heywood. “The company is advancing multiple mid-clinical stage programs based on its first-in-class Ammonia Oxidizing Bacteria (AOB) platform, which we expect will have key data readouts over the course of the next year and into 2019. Todd’s exemplary track record and his unique expertise across healthcare strategy, business development, and operations will be essential in guiding the company through its next stage of development.”

Mr. Krueger joined AOBiome in May 2015 as Chief Business Officer, prior to which he served as Head of Commercial Strategy and Operations for the Genomics Platform at the Broad Institute. Previously, Mr. Krueger held senior positions at Life Technologies, including Head of Business Development for Genetic Systems and Head of Business Development for Molecular Medicine, focused on the company’s companion diagnostics business. He has also been involved in the founding of several biotechnology companies, including Gynesonics, Nodality, and Anestis Therapeutics. In 1999, he co-founded Fluidigm Corporation, a publicly traded life sciences technologies and tools company, where he served as CFO and Vice President of Business Development. Mr. Krueger is a member of the Board of Directors for multiple companies, including General Automation Lab Technologies (GALT), a microbiome tools company. He started his career as a consultant for Bain and Company in Boston. Mr. Krueger graduated Highest Distinction from Northwestern University with a degree in Economics and earned his MBA from the Kellogg School of Management.

“It has been a privilege to work closely with the accomplished team at AOBiome as we have advanced and expanded our development pipeline targeting diverse inflammatory conditions,” said Todd Krueger, President of AOBiome. “In 2018 and beyond we will continue to focus on developing innovative clinical programs and applying our world-class scientific platform to address areas of compelling unmet patient needs.”

About AOBiome

AOBiome Therapeutics is a Boston-based life sciences company focused on transforming human health by developing microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Founded in 2013 by PatientsLikeMe founder Jamie Heywood and MIT Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company’s portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. Learn more at


For Media Inquiries Justin Jackson
212-213-0006, ext. 327
[email protected]

Recent News
23 April 2018, Cambridge, MA
AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine

21 March 2018, Cambridge, MA
AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery

4 January 2018, Cambridge, MA
AOBiome Therapeutics Appoints Todd Krueger as Chief Executive Officer

19 October 2017, Cambridge, MA
AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris

3 October 2017, Cambridge, MA
AOBiome Commences Patient Enrollment in Phase 1b/2a Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Seasonal Allergic Rhinitis

20 September 2017, Cambridge, MA
AOBiome Expands Intellectual Property Estate, Announces Issuance of U.S. Patent for Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne

13 April 2017, Cambridge, MA
AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure

4 March 2017, Cambridge, MA
American Academy of Dermatology selects AOBiome study for presentation at Annual Meeting

5 January 2017, Cambridge, MA
AOBiome Partners with iCarbonX and Secures $30 Million Investment for Drug Development

16 December 2016, Cambridge, MA
AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

20 September 2016, Cambridge, MA
AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment for Acne

31 December 2015, Cambridge, MA
AOBiome Wins Dermatology Entrepreneurship Shark Tank Contest

7 July 2015, Cambridge, MA
Mother Dirt Rethinks what it means to be Clean and Healthy with First-Ever Line of Biome-Friendly Products for the Skin

29 June 2015, Cambridge, MA
AOBiome co-founder, Jamie Heywood named by Scientific American, as one of The Worldview 100, The visionaries who continue to reshape biotechnology-and the world

22 June 2015, Cambridge, MA
AOBiome Announces Start of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic for Treatment of Acne

18 May 2015, Cambridge, MA
AOBiome Announces Three Senior Management Appointments

2 Oct 2014, Washington, DC
American Society for Microbiology Reports Sweat-Eating Bacteria May Improve Skin Health

20 Jun 2014, Cleveland, OH
Accelerated Healing of Diabetic Ulcer Data Presented

16 Jun 2014, Cambridge, MA
AOBiome in the News

19 May 2014, Cambridge, MA
AOBiome announces appointment of scientific advisory board

30 Jun 2013, Cambridge, MA
Nitrocell becomes AOBiome LLC